Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT116 in Combination With Ivonescimab (AK112) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07590531Phase 2Recruiting
- Sponsor
- Multitude Therapeutics
- Start
- Jun 2026
- Primary completion
- May 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of AMT-116 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Multitude Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 10 months, Dose Limiting Toxicities at 10 months and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
AMT-116
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07590531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07590531.